Sonomedical to open the third unit in Spain

The Spanish healthcare technology company, Sonomedical, focused on non-invasive treatments of thyroid nodules using ultrasound, has opened its third specialized unit in Spain, which is located in the Sagrada Familia Clinic in Barcelona.

Born2Invest is a digital media website covering the biotech industry, among others. Our companion app allows you to get your daily dose of financial news from industries like banking, cannabis, innovation in biotechnology. The Born2Invest application is aggregating the most important and breaking news from relevant websites, the list is always revised and updated with new resources.

The company uses technology based on high-intensity focused ultrasound (Hifu)

Specifically, Sonomedical has been operating a thyroid nodule treatment unit at the center owned by Laboratorios Echevarne since 2016. The equipment alone will cost approximately $0.55 million (€0.5 million), according to the management of Sonomedical, although they pointed out that there are other associated indirect costs.

“We share the philosophy of the Echevarne family very well. It is a clinic that is undergoing a process of renovation and with which we see that we can establish great synergies in endocrinology,” explained the company.

This department is coordinated by Dr. Guillem Cuatrecasas, who will work with the medical management of Sonomedical, led by Paco Ortiz Remacha. The Echevarne group, currently run by the brothers Alfonso and Fernando Echevarne Santamaría, recorded a turnover of $184 million (€168 million) in 2018. Earnings before interest, taxes, depreciation, and amortization (Ebitda) were $27 million (€24.5 million) at the end of last year.

The Barcelona unit joins the ones that Sonomedical has at the Santa Elena Clinic, a center that depends on the Hospitales Católicos in Madrid, and the Viamed Montecanal Hospital in Zaragoza. At these facilities, the company uses technology based on high-intensity focused ultrasound (Hifu).

Sonomedical plans to reach 20 locations by 2024

Sonomedical is committed to being in around twenty medical facilities over the next four years. The company explained that within the national territory, the next community where it will be implemented will be Andalusia.

Outside the Spanish borders, the company is focusing its plans on new openings in Italy and the United Kingdom. “We are in negotiations with our manufacturer to open soon in these countries,” the company said. The manufacturing company with which Sonomedical works is the French company Theraclion, a company listed on Euronext Growth Paris.

An equity loan was requested last year by Sonomedical to secure its development

To sustain its growth, Sonomedical requested an $8.78 million (€8 million) equity loan last year. Initially, the company planned to open a financing round of $1.65 million (€1.5 million), a forecast that fell short.

The prevalence of people affected by thyroid nodules is seven million and the vast majority of these are benign, while around 5% are malignant. It is estimated that the percentage of people affected by thyroid nodules in Spain is ten points below the decade in which they are found. For example, at the age of forty we would speak of a 30% prevalence, reaching rates of more than 50% from the age of sixty.

__

(Featured image by jarmoluk via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.